Morphic Holding (MORF) Stock Price

Morphic Holding Price

🇺🇸NASDAQ·CLOSED
56.99USD
Market closed
Today +/-
Today %

Morphic Holding (MORF) Stock | ISIN US61775R1059 | WKN A2PLX9. The current Morphic Holding stock price is 56.99 USD (2026). Revenue is 408,000 USD. Net income is -226.92 M USD. The P/E ratio is -10.65. Market capitalization is 2.86 B USD. Morphic Holding operates in the Health sector.

Morphic Holding stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Morphic Holding over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Morphic Holding stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Morphic Holding's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Morphic Holding Stock Price History
DateMorphic Holding Price
Access this data via the Eulerpool API

Morphic Holding Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0 USD
-16.93 M USD
-16.92 M USD
Jan 1, 2018
3.36 M USD
-24.63 M USD
-23.83 M USD
Jan 1, 2019
16.98 M USD
-46.99 M USD
-43.33 M USD
Jan 1, 2020
44.95 M USD
-47.18 M USD
-45 M USD
Jan 1, 2021
19.79 M USD
-95.81 M USD
-95.54 M USD
Jan 1, 2022
70.81 M USD
-63.4 M USD
-59.04 M USD
Jan 1, 2023
521,000 USD
-178.69 M USD
-152.1 M USD
Invalid Date
255,000 USD
-228.7 M USD
-204.56 M USD
Invalid Date
291,424.19 USD
-248.56 M USD
-217.58 M USD
Invalid Date
408,000 USD
-272.2 M USD
-226.92 M USD
Invalid Date
1.22 M USD
-312.28 M USD
-254.79 M USD
Invalid Date
156.53 M USD
-226.39 M USD
-175.29 M USD

Morphic Holding Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 12, 2026, 5:14 PM
 
REVENUE (M USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
202220232024e2025e2026e2027e2028e2029e
7000001156381
268.4215,500144.23
----
00000000
-59-152-204-217-226-254-175-58
-37.89157.6334.216.374.1512.39-31.1-66.86
38.1142.3942.3942.3942.3942.3942.3942.39
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Morphic Holding generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Morphic Holding retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Morphic Holding's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Morphic Holding has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Morphic Holding's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Morphic Holding stock margins

The Morphic Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Morphic Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Morphic Holding.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
0 %
- %
- %
Jan 1, 2018
0 %
-733.04 %
-709.23 %
Jan 1, 2019
0 %
-276.74 %
-255.18 %
Jan 1, 2020
0 %
-104.96 %
-100.11 %
Jan 1, 2021
0 %
-484.13 %
-482.77 %
Jan 1, 2022
0 %
-89.54 %
-83.38 %
Jan 1, 2023
0 %
-34,296.74 %
-29,192.9 %
Invalid Date
0 %
-89,687.11 %
-80,218.01 %
Invalid Date
0 %
-85,291.25 %
-74,659.43 %
Invalid Date
0 %
-66,715.96 %
-55,618.65 %

Morphic Holding Stock Revenue, EBIT, Earnings per Share

The Morphic Holding earnings per share therefore indicates how much revenue Morphic Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0 USD
-0.57 USD
-0.57 USD
Jan 1, 2018
0.11 USD
-0.83 USD
-0.81 USD
Jan 1, 2019
0.56 USD
-1.56 USD
-1.44 USD
Jan 1, 2020
1.47 USD
-1.54 USD
-1.47 USD
Jan 1, 2021
0.55 USD
-2.68 USD
-2.67 USD
Jan 1, 2022
1.86 USD
-1.66 USD
-1.55 USD
Jan 1, 2023
0.01 USD
-4.22 USD
-3.59 USD
Invalid Date
0.01 USD
-5.4 USD
-4.07 USD
Invalid Date
0.01 USD
-5.86 USD
-4.33 USD
Invalid Date
0.01 USD
-6.42 USD
-4.52 USD

Morphic Holding business model & stock analysis

Morphic Holding Inc. is a pharmaceutical company that focuses on developing therapies for serious diseases. The company was founded in 2015 and is based in Waltham, Massachusetts. The company's business model is centered around developing drugs based on "Morphic Molecules" that are specifically designed to interact with certain target proteins in the body. These molecules aim to improve the treatment of diseases such as autoimmune diseases and fibrosis. Morphic Holding Inc. collaborates closely with leading scientists in the field of structural biology to develop new therapy options for patients. The company has formed partnerships with Biogen, Janssen Biotech, and AbbVie to collaboratively develop new medications. In addition to partnering with other leading companies in the healthcare industry, Morphic Holding Inc. also maintains its own research department focused on the discovery and development of new compounds. The company has applied for and been granted several patents for its "Morphic Molecules," further strengthening its ability to develop innovative therapies for serious diseases. One of Morphic Holding Inc.'s current products is a drug for the treatment of cystic fibrosis that is still in the development phase. The company is working to advance its research and development in this area to continue offering innovative therapies for patients. Morphic Holding Inc. is also involved in biotechnological development and offers services to assist other companies in developing new compounds. These services include the identification and validation of target proteins, the design and synthesis of molecules, and the optimization of drug properties. In conclusion, Morphic Holding Inc. is an emerging force in the pharmaceutical development field. The company has a unique approach to drug development and has already established partnerships with other companies and leading research institutions to develop new therapy options for patients. With its commitment to innovation and research, Morphic Holding Inc. is likely to continue making significant advancements in the field of medicine in the future.

Morphic Holding SWOT Analysis

Strengths

Morphic Holding Inc possesses several strengths that contribute to its success in the market. One of its key strengths is its strong and experienced management team, which has a deep understanding of the industry. This enables the company to make informed decisions and navigate challenges effectively.

Furthermore, Morphic Holding Inc has a diverse portfolio of innovative products and solutions, which gives it a competitive edge in the market. Its focus on research and development ensures that it stays ahead of its competitors by continuously improving and expanding its offerings.

Weaknesses

While Morphic Holding Inc has numerous strengths, it also faces certain weaknesses that need to be addressed. One of its weaknesses is its limited market presence compared to some of its larger competitors. This makes it more challenging for the company to penetrate new markets and gain significant market share.

Additionally, Morphic Holding Inc heavily relies on a few key customers for a significant portion of its revenue. This dependency poses a risk, as any loss of these customers could have a negative impact on the company's financial performance.

Opportunities

There are several opportunities available for Morphic Holding Inc to capitalize on and fuel its growth. The increasing demand for its products and solutions, driven by market trends and technological advancements, presents a significant opportunity for the company to expand its customer base and increase its market share.

Furthermore, the company has the potential to enter new geographic markets where its products are not yet widely available. By strategically targeting these untapped markets, Morphic Holding Inc can tap into new revenue streams and diversify its customer base.

Threats

Despite its strengths and opportunities, Morphic Holding Inc also faces certain threats that could impact its performance. One of the major threats is intense competition from established players in the industry. This competition can lead to pricing pressures and reduced market share if the company is unable to differentiate itself effectively.

Moreover, regulatory changes and compliance requirements pose a potential threat to Morphic Holding Inc. Changes in regulations or non-compliance with existing ones can create operational challenges and legal liabilities, affecting the company's reputation and financial stability.

Morphic Holding Segments

Morphic Holding Eulerpool Fair Value

Morphic Holding historical P/E ratio, EBIT multiple, and P/S ratio

Morphic Holding annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Morphic Holding shares outstanding

The number of shares was Morphic Holding in 2025 — This indicates how many shares 42.391 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
29.6 M base_Shares
Jan 1, 2018
29.6 M base_Shares
Jan 1, 2019
30.11 M base_Shares
Jan 1, 2020
30.59 M base_Shares
Jan 1, 2021
35.8 M base_Shares
Jan 1, 2022
38.11 M base_Shares
Jan 1, 2023
42.39 M base_Shares
Invalid Date
42.39 M base_Shares
Invalid Date
42.39 M base_Shares
Invalid Date
42.39 M base_Shares
Price targets and forecasts for Morphic Holding are not yet available.

Morphic Holding Earnings Estimates

Morphic Holding Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/23/2024-0.97USD0USD2024 Q1
2/21/2024-0.87USD0USD2023 Q4
8/1/2023-0.85USD2.64 MUSD2023 Q2
5/2/2023-0.86USD2.47 MUSD2023 Q1
2/22/2023-0.89USD2.74 MUSD2022 Q4
11/2/2022-0.85USD3.28 MUSD2022 Q3
8/3/2022-0.87USD3.13 MUSD2022 Q2
5/4/2022-0.83USD3.16 MUSD2022 Q1
2/24/2022-0.5USD12.57 MUSD2021 Q4
11/4/2021-0.77USD5.27 MUSD2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Morphic Holding stock

47/100
49
Environment
61
Social
30
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Morphic Holding shareholder structure

% Name
6.02575%
Springer Timothy A
Springer Timothy A
3.96386%
Polaris Venture Partners
Polaris Venture Partners
1.22356%
Tipirneni (Praveen P)
Tipirneni (Praveen P)
0.29132%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
0.25679%
Medical Strategy GmbH
Medical Strategy GmbH
0.06587%
Wellington Management Singapore Pte. Ltd.
Wellington Management Singapore Pte. Ltd.
0.06322%
Wellington Management Japan Pte Ltd
Wellington Management Japan Pte Ltd
0.04414%
DeVaul (William David)
DeVaul (William David)
0.03086%
T. Rowe Price Japan, Inc.
T. Rowe Price Japan, Inc.
0.0275%
Neuberger Berman Investment Advisors LLC
Neuberger Berman Investment Advisors LLC
...

Morphic Holding Executives and Management Board

MT

Mr. Michael Thompson

President, Treasurer, Director · since 2024

KL

Ms. Katie Lodato

Assistant Treasurer

CA

Mr. Christopher Anderson

Company Secretary, Director · since 2024

JG

Mr. Jonathan Groff

Assistant Secretary

GB

Mr. Gordon Brooks

Director

Morphic Holding Supply Chain

Frequently asked questions about Morphic Holding

The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.

All fundamentals and in-depth analysis of Morphic Holding

Our stock analysis for Morphic Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Morphic Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.